IVF Explained Step by Step: What to Expect From Your First Consultation to Embryo Transfer

In vitro fertilization is the process by which eggs are retrieved from the ovaries, fertilized with sperm in a laboratory, cultured to the embryo stage, and transferred into the uterus to achieve pregnancy. It is the most effective assisted reproductive technology available and has resulted in the birth of more than 8 million people worldwide since Louise Brown, the first IVF baby, was born in 1978. In the United States, approximately 2.3% of all babies born each year are conceived through IVF, and the Centers for Disease Control and Prevention reports that more than 238,000 IVF cycles are performed annually. Despite its prevalence, IVF remains poorly understood by most people facing infertility — which means patients enter the process with anxiety amplified by uncertainty. Understanding each step, what to expect, and what the numbers actually mean transforms that uncertainty into informed decision-making.

Who Is IVF For?

IVF is recommended for a range of infertility diagnoses. Common indications include blocked or damaged fallopian tubes (where natural fertilization cannot occur), male factor infertility with severely reduced sperm count, motility, or morphology, ovulation disorders including PCOS that do not respond adequately to oral induction agents, endometriosis affecting the fallopian tubes or ovaries, diminished ovarian reserve, unexplained infertility that has not resolved after 1–2 years and simpler interventions, genetic conditions requiring preimplantation genetic testing, and same-sex couples or single individuals using donor sperm or eggs.

IVF is generally not the first-line intervention for unexplained infertility in younger patients — less invasive options including intrauterine insemination (IUI) with ovarian stimulation are typically tried first. The decision to proceed to IVF is made based on diagnosis, age, and ovarian reserve testing results.

Step 1: The Initial Consultation and Baseline Testing

Before an IVF cycle begins, both partners (or the individual patient and donor) undergo a comprehensive fertility evaluation. For women this includes: anti-Müllerian hormone (AMH) — a marker of ovarian reserve that reflects how many follicles are available; an antral follicle count (AFC) by transvaginal ultrasound, which directly counts resting follicles at the start of a cycle; FSH and estradiol levels on cycle day 2 or 3; a uterine evaluation by ultrasound or hysteroscopy to identify fibroids, polyps, or structural anomalies that could impair implantation; and full infectious disease screening (HIV, hepatitis B and C, syphilis, rubella immunity).

For male partners: a complete semen analysis measuring volume, count, concentration, motility, and morphology using Kruger strict criteria (normal morphology is typically defined as ≥4% normal forms). If severe abnormalities are found, a reproductive urologist evaluation may be recommended before proceeding, as some causes of male infertility are correctable.

Low AMH, elevated FSH, or a low antral follicle count indicate diminished ovarian reserve and may predict a poor response to stimulation, meaning fewer eggs retrieved. These numbers guide medication dosing decisions and realistic expectations-setting conversations about outcomes.

Step 2: Ovarian Stimulation

In a natural cycle, one dominant follicle develops and releases one egg at ovulation. IVF requires multiple eggs to maximize the number of embryos available for transfer and selection. Ovarian stimulation with injectable gonadotropins — typically a combination of FSH (such as follitropin alfa/Gonal-F or follitropin beta/Follistim) and LH activity — recruits and grows multiple follicles simultaneously.

Stimulation protocols vary by clinic and patient profile but generally run for 8 to 14 days. During this period, patients self-inject medications once or twice daily and attend clinic monitoring appointments every 1 to 3 days for transvaginal ultrasound and blood estrogen (E2) levels. These appointments track follicle growth and number, allowing medication doses to be adjusted. The goal is typically to develop 8–15 mature follicles while monitoring carefully for ovarian hyperstimulation syndrome (OHSS).

GnRH Agonist vs. Antagonist Protocol

To prevent premature ovulation (releasing the eggs before retrieval), a GnRH agonist (like leuprolide) or GnRH antagonist (like cetrorelix or ganirelix) is added. Antagonist protocols, which add the suppression medication mid-stimulation, have become the preferred approach at most centers because they allow a GnRH agonist trigger (instead of hCG) for final egg maturation, dramatically reducing OHSS risk.

The Trigger Shot

When leading follicles reach approximately 17–20 mm diameter and estrogen levels align with follicle count, a trigger injection is administered to finalize egg maturation. Egg retrieval is scheduled precisely 35–36 hours after the trigger, timed to the hour to capture eggs before natural ovulation.

Step 3: Egg Retrieval

Egg retrieval is a minor surgical procedure performed under IV sedation, typically 20 to 30 minutes long. A transvaginal ultrasound probe with an attached needle guide is used to aspirate each follicle through the vaginal wall. Fluid from each follicle is immediately passed to an embryologist who identifies the eggs under a microscope. The number of eggs retrieved can range from 1–2 in poor responders to 20 or more in high responders.

Recovery from retrieval takes several hours at the clinic. Mild to moderate pelvic cramping and bloating are normal in the following 1–5 days. Most patients return to normal activities within 24–48 hours. Rare but serious complications include infection (less than 0.5%) and significant bleeding (less than 0.5%). OHSS, discussed below, is the most clinically significant risk.

Step 4: Fertilization

Retrieved eggs are assessed for maturity. Only mature (MII stage) eggs can be fertilized. Fertilization is performed by one of two methods:

• Conventional insemination: A prepared sperm sample is placed in a dish with each egg and natural fertilization is allowed to occur — appropriate when sperm parameters are normal.
• Intracytoplasmic sperm injection (ICSI): A single sperm is injected directly into each mature egg using a fine needle under high-powered microscopy. ICSI is used when sperm count, motility, or morphology is significantly reduced, after prior fertilization failure, or as standard practice at many clinics. ICSI has not been shown to improve outcomes over conventional insemination when sperm parameters are normal.

Fertilization results are confirmed 16–18 hours after insemination. Normal fertilization shows two pronuclei (2PN). Fertilization rates are approximately 60–80% of mature eggs. Not all retrieved eggs are mature, and not all mature eggs fertilize normally — these sequential attrition steps are important for expectation-setting.

Step 5: Embryo Culture

Fertilized eggs (embryos) are cultured in specialized incubators mimicking the conditions of the fallopian tube and uterus, typically for 5 to 6 days to the blastocyst stage. Blastocysts — embryos with a distinct inner cell mass and surrounding trophectoderm layer — have better implantation rates and are more informative for genetic testing than Day 3 cleavage-stage embryos. Blastocyst formation rates are approximately 30–50% of fertilized eggs.

Not all fertilized embryos reach blastocyst stage — this is expected and reflects the natural attrition that occurs in vivo as well. A couple who starts with 8 retrieved eggs might have 6 mature, 4–5 fertilized, and 2–3 blastocysts by Day 5.

Step 6: Preimplantation Genetic Testing (PGT)

PGT is optional but increasingly utilized. The most common form, PGT-A (preimplantation genetic testing for aneuploidy), biopsies 4–8 cells from the trophectoderm (future placenta) of each blastocyst and analyzes all 24 chromosomes. Embryos with the correct chromosome number (euploid) are selected for transfer; aneuploid embryos have a high rate of miscarriage and implantation failure and are not transferred.

The proportion of chromosomally normal embryos declines sharply with age: approximately 70–75% of blastocysts from women under 35 are euploid, falling to approximately 40–45% at ages 38–40, and below 20% at 43 and above. This decline in euploid embryo rate is the primary biological mechanism behind declining IVF success rates with age, not simply diminished egg numbers. PGT-A reduces miscarriage rates and increases per-transfer success rates but requires a freeze-all cycle (all embryos frozen, transfer in a subsequent cycle) to allow time for biopsy results.

Step 7: Embryo Transfer

Embryo transfer is a straightforward office procedure performed without anesthesia in most cases — similar in feeling to a Pap smear. A thin flexible catheter is guided through the cervix under ultrasound guidance and the embryo is deposited in the uterine cavity. Most clinics transfer one euploid blastocyst at a time (single embryo transfer, or SET) to maximize success rates while minimizing twin risks. Twins from IVF carry significantly higher rates of premature birth, low birth weight, and maternal complications.

Fresh vs. Frozen Embryo Transfer

Fresh transfers occur 3–5 days after retrieval in the same cycle. Frozen transfers (FET) occur in a subsequent cycle after embryos have been vitrified (ultra-rapid frozen). Cumulative data shows FET in a natural or medicated cycle typically achieves equivalent or slightly better outcomes than fresh transfer, particularly for OHSS-risk patients, patients with thin uterine lining, or when PGT-A is performed. Most current IVF cycles use a freeze-all strategy with FET.

IVF Success Rates: What the Numbers Actually Mean

Success rates are most meaningfully expressed as live birth rates per transfer using the patient's own eggs, stratified by age. 2022 SART (Society for Assisted Reproductive Technology) data shows approximately:

• Under 35: ~50–55% live birth rate per transfer
• 35–37: ~40–45%
• 38–40: ~25–35%
• 41–42: ~15–22%
• Over 42: ~3–7% (own eggs)

These statistics apply per transfer, not per retrieval cycle. Multiple transfers using embryos from a single retrieval can substantially increase cumulative success rates. Donor egg IVF in recipients over 40 achieves live birth rates of 45–55%, similar to younger patients' own-egg rates, because the egg quality is normalized.

What IVF Costs in the USA

A single IVF cycle in the United States costs approximately $12,000 to $17,000 without insurance, before the cost of medications (typically an additional $3,000 to $7,000), genetic testing ($1,500 to $4,000), or embryo storage fees. Many patients require multiple cycles. Insurance coverage is mandated in 20 states as of 2024, though coverage requirements vary significantly. Fertility financing programs and multi-cycle packages from clinics can lower per-cycle costs. It is one of the more significant financial undertakings in reproductive medicine and should be discussed transparently with the clinic's financial coordinator before starting.

The Emotional Toll of IVF

The psychological burden of IVF is real and clinically recognized. Daily injections, frequent monitoring appointments, the procedural experience of retrieval, the waiting period between retrieval and transfer results, and the profound vulnerability of each pregnancy test create a level of emotional stress that is genuinely difficult. Anxiety and depression are more common in people undergoing IVF than in the general population. Studies show that psychological support — whether individual therapy, support groups, or couples counseling — improves quality of life and may modestly improve outcomes. Asking for psychological support during IVF is not weakness; it is good clinical care.

What Happens When IVF Fails

Failed cycles are common, particularly in older patients or those with complex diagnoses. When a cycle fails, the clinical review examines several factors: fertilization rate, blastocyst development rate, embryo chromosome status (if PGT was performed), uterine receptivity testing (ERA — endometrial receptivity assay), and whether a hysteroscopy is warranted to rule out uterine pathology. Sometimes protocol adjustments improve outcomes in subsequent cycles. Sometimes the honest answer is that egg quality is the limiting factor and donor egg IVF is the pathway to parenthood that will actually work.

When to See a Doctor

If you have been trying to conceive for 12 months without success (or 6 months if over 35, or immediately if you have a known diagnosis such as blocked tubes, PCOS, or a partner with known low sperm count), a fertility evaluation is appropriate. Early evaluation changes outcomes — ovarian reserve declines with time and cannot be recovered. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

How many IVF cycles does it usually take to get pregnant?

For women under 35, cumulative live birth rates reach approximately 80–90% after three cycles, meaning most patients who persist will achieve pregnancy. In older patients or those with diminished ovarian reserve, cumulative rates remain substantially lower. There is no clinical rule about how many cycles to attempt — the decision depends on financial capacity, emotional reserves, and an honest discussion with your physician about realistic prospects with further cycling versus alternatives such as donor eggs or adoption.

Is IVF painful?

The stimulation injections involve daily subcutaneous injections that most patients describe as mildly uncomfortable but manageable — similar to a pinch. Bloating and pelvic pressure are common during stimulation as follicles grow. Egg retrieval is performed under IV sedation and is not painful during the procedure; post-retrieval cramping and bloating typically last 1–5 days. Embryo transfer is generally no more uncomfortable than a Pap smear for most patients.

Does IVF increase the risk of cancer?

Decades of data on ovarian stimulation have not established a meaningful increase in ovarian cancer risk from IVF. The association between fertility drugs and borderline ovarian tumors seen in early studies is now thought to reflect underlying infertility itself, not the medications. Large registry studies have not found increased risks of breast, uterine, or ovarian cancer in IVF patients. Women with BRCA mutations should discuss with their oncology and fertility teams whether the stimulation hormone exposure is a concern in their specific context.

What is ovarian hyperstimulation syndrome (OHSS)?

OHSS occurs when the ovaries respond excessively to stimulation, causing them to become enlarged and leaky. Mild OHSS — bloating, abdominal discomfort, weight gain — is common after retrieval and resolves on its own. Severe OHSS involves significant fluid accumulation in the abdomen and chest, concentrated blood, and risk of blood clots, and requires medical management. The risk of severe OHSS has been substantially reduced by the use of GnRH agonist triggers (instead of hCG) in high-responder patients and the adoption of freeze-all strategies that avoid fresh transfer during the stimulation cycle.

Can I choose the sex of my baby with IVF?

Sex selection is technically possible through PGT-A, which identifies the chromosomal sex of each embryo. In the United States, sex selection for non-medical reasons is legal and performed at some clinics, though it is controversial and not offered universally. Sex selection is medically indicated for couples carrying X-linked genetic conditions (such as hemophilia or Duchenne muscular dystrophy) who wish to transfer only embryos of the unaffected sex. Most mainstream professional societies discourage sex selection for non-medical preference, and some clinics decline to perform it.